No clinical trial data support claims related to bodybuilding or muscle gain, as the conducted trials excluded athletes and focused on endocrine deficits
Wegovy (Semaglutide for Chronic Weight Management) FDA indication: Chronic weight management in adults with BMI 30 or greater, or BMI 27 or greater with at least one weight-related comorbidity Approved doses: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg (weekly subcutaneous injection) Target maintenance dose: 2.4 mg weekly Pediatric indication: Approved for adolescents aged 12 and older with obesity Ozempic (Semaglutide for Type 2 Diabetes) FDA indication: Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes Approved doses: 0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg (weekly subcutaneous injection) Note: Not FDA-approved for weight management, though frequently prescribed off-label Rybelsus (Oral Semaglutide) FDA indication: Type 2 diabetes management Doses: 3 mg, 7 mg, 14 mg (daily oral tablet) Lower bioavailability: Oral formulation has approximately 1% bioavailability, resulting in less predictable weight loss compared to injectable forms Comprehensive semaglutide training for physicians emphasizes the importance of prescribing the correct formulation for the correct indication
See our compound semaglutide with B12 guide for details on compounded formulations
NPs were prepared as previously reported ( 71 )
How do I inject Tirzepatide
